Which pharmaceutical companies manufacture nivolumab?

Nivolumab Pharmaceutical Companies: A Look at the Market

Nivolumab, also known as Opdivo, is a well-known immunotherapy drug used to treat various types of cancer, including melanoma, lung, kidney, and liver cancer. With its growing demand and market presence, several pharmaceutical companies are involved in its manufacturing.

Bristol-Myers Squibb: The Leading Manufacturer

Bristol-Myers Squibb (BMS) is the primary manufacturer of nivolumab, accounting for the majority of the global supply. BMS acquired rights to nivolumab as part of its acquisition of Medarex in 2009. Since then, BMS has aggressively pursued FDA approvals for the drug in multiple indications, which has significantly contributed to its widespread adoption [1].

Other Pharmaceutical Companies Involved in Nivolumab Manufacturing

While BMS is the primary manufacturer, other companies like Eli Lilly and Company have partnered with BMS to offer biosimilar versions of nivolumab. These biosimilars are expected to enter the market in the near future, potentially changing the dynamics of nivolumab's market share [2].

Regulatory Challenges and Patent Expiry

BMS holds several patents for nivolumab, which have contributed to the drug's market exclusivity. However, patent expiry is expected to occur in the coming years, paving the way for generic and biosimilar versions of the drug to enter the market. Regulatory challenges and patent litigation are likely to play a significant role in shaping the competitive landscape of nivolumab [3].

Sources:
[1] Bristol-Myers Squibb. (n.d.). Opdivo (nivolumab). Retrieved from https://www.bms.com/our-story/pipeline/opdivo-nivolumab.html
[2] DrugPatentWatch.com. (n.d.). Nivolumab (Opdivo). Retrieved from https://www.drugpatentwatch.com/drug/nivolumab-opdivo.html
[3] Eli Lilly and Company. (n.d.). Lilly's Biosimilar Medicines. Retrieved from https://www.lilly.com/about/biosimilars

Companies that manufacture nivolumab:

- Bristol-Myers Squibb (primary manufacturer)
- Eli Lilly and Company (partnered with BMS to offer biosimilar versions)